Biofilms are thought to play an important role in the pathogenesis of CRS and the effects of topical bactericidal agents on these biofilms has been widely investigated. However, topical corticosteroids are first-line therapy in the medical management of chronic rhinosinusitis, and these topical agents are postulated to work through an anti-inflammatory mechanism rather than a bactericidal one. Goggin et al. aimed to examine whether or not the most common topical nasal corticosteroids used (mometasone, budesonide, and fluticasone) have any direct action against biofilms in an in vitro setting.
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The study was designed as an in vitro comparative control trial. Staphylococcus aureus biofilms were grown from commercially obtained S. aureus bacteria. Biofilm-coated pegs were exposed separately to three different corticosteroid solutions (mometasone, budesonide, and fluticasone) at a range of increasing corticosteroid concentrations (mometasone and fluticasone, 25-400 g/200 L; budesonide, 16 -2000 g/200 L). Both corticosteroids and controls were placed in a solvent, dimethyl sulfoxide, and each corticosteroid was tested four times. Biofilm pegs were exposed to corticosteroid or control solutions for 48 hours and then washed with saline to remove excess planktonic bacteria and, finally, placed in fixative. A confocal scanning laser microscope was used to determine the remaining biofilm mass.
Fluticasone significantly reduced biofilm concentrations compared with controls (96% reduction) only at the highest concentration (400 g/200 L; recommended therapeutic dose, 200 g). Mometasone reduced biofilm concentrations compared with controls at concentrations of 300 (65% reduction) and 400 g/200 L (98% reduction; recommended therapeutic dose, 200 g). Finally, budesonide significantly reduced biofilm mass compared with controls at the higher concentrations of 750 (98% reduction), 1000 (99% reduction), and 2000 g/200 L (99% reduction; recommended therapeutic dose, 256 g for nasal spray and 1000 g for Respules). Budesonide had no significant effect at concentrations less than 500 g.
The strength of this study is that it is the first to show that topical corticosteroids may have an antibiofilm action. Additionally, the study design is sound, because corticosteroid solutions are matched with appropriate controls. However, one is left questioning the in vivo applicability of the results. The steroids are applied to the bacterial pegs for 48 hours, which does not mirror what occurs in the patient. Also, a solvent is used in the experiment, dimethyl sulfoxide, and it is unclear what if any cumulative effect against the integrity of the biofilm that this solvent may have when placed in combination with a corticosteroid. Finally, only one type of bacterial biofilm is examined, S. aureus, and these results may not be replicated in other bacteria such as Pseudomonas aeruginosa.
The main conclusion from this control trial is that topical corticosteroids appear to inhibit biofilm formation in an in vitro setting. This result is seen at concentrations of corticosteroids that are greater than manufacturer recommended doses for topical nasal sprays. In the case of budesonide, these effects are seen at concentrations similar to those obtained in a Respules dose. Although the steroid exposure times are greater than what would occur in a typical in vivo setting, it does provide solid evidence for the antibiofilm properties of topical corticosteroids. Unclear is by what physiological mechanism corticosteroids inhibit biofilms, and this must be better elucidated using in vitro models. Finally, an in vivo study is the ultimate goal. The data provided here by Goggin et al. suggests that this may be best accomplished using higher concentrations of corticosteroids, such as those used in Respules, or with longer-lasting corticosteroid mediums.
